Human papillomavirus disease and vaccines (Q37321854)

19 August 2017

1 reference

title

Human papillomavirus disease and vaccines (English)

1 reference

19 August 2017

main subject

human papilloma virus

1 reference

human papillomavirus

29 September 2024

David J Hutchinson

1 reference

19 August 2017

Kristin C Klein

series ordinal

1 reference

19 August 2017

publication date

1 November 2008

1 reference

American Journal of Health-System Pharmacy

19 August 2017

published in

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

2105-2112

1 reference

Review of the economic and quality-of-life burden of cervical human papillomavirus disease

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

The epidemiology of human papillomavirus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Natural History of Cervicovaginal Papillomavirus Infection in Young Women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Epidemiologic classification of human papillomavirus types associated with cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

The causal relation between human papillomavirus and cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

31 March 2020

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Cofactors With Human Papillomavirus in a Population-Based Study of Vulvar Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

A population-based study of squamous cell vaginal cancer: HPV and cofactors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Genital human papillomavirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

External genital warts: diagnosis, treatment, and prevention.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Prophylactic HPV vaccines: reducing the burden of HPV-related diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Human papillomavirus vaccines launch a new era in cervical cancer prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Politics, parents, and prophylaxis--mandating HPV vaccination in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Youth risk behavior surveillance--United States, 2005.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Health and economic implications of HPV vaccination in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

HPV vaccine: immersed in controversy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

Human papillomavirus vaccine--opportunity and challenge.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

HPV vaccination--more answers, more questions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070627

31 March 2020

Identifiers

DOI

10.2146/AJHP070627

1 reference

19 August 2017

1 reference